Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
5. ICU Medical closes $900m buyout of Pfizer’s Hospira infusion pump biz
ICU Medical this week closed its $900 million acquisition of the Hospira infusion pump business from Pfizer, confirming last year’s rumors that the drug giant was looking to sell the business.
The deal, which was scaled back from $1 billion last month, called for ICU Medical to offer 3.2 million new shares, or $419.3 million, and $275 million in cash, along with an additional possible $225 million in cash based on performance milestones through the end of 2019. The transaction will put Hospira’s infusion systems business, including IV pumps, solutions, disposables and “certain other assets” in ICU Medical’s hands, while Pfizer will hold a 16.6% stake in ICU. Read more
4. Zimmer Biomet wins CE Mark for Subchondroplasty bone marrow lesion procedure
Zimmer Biomet said today it won CE Mark approval in the European Union for its for the Subchondroplasty procedure designed to treat subchondral bone marrow lesions.
The Warsaw, Ind.-based company’s minimally invasive procedure is designed to repair chronic BMLs includes filling them with AccuFill bone substitute material which is slowly resorbed and replaced with healthy bone. Read more
3. Owlstone Medical launches 1,400-patient study for colon cancer ‘breathalyzer’
Owlstone Medical said today it is launching a 1,400-patient clinical trial of its breath-based colorectal cancer diagnostic technology.
The Intercept trial aims to explore the accuracy of the U.K.-based company’s ‘breathalyzer’ test in detecting colorectal cancer at an early stage. Read more
2. Sens. Sanders, Cruz talk drug pricing, Obamacare in town hall debate
Sens. Bernie Sanders (I-Vermont) and Ted Cruz (R-Texas) met last night to debate the future of Obamacare in a town-hall debate. The 2 senators are opposed on how to provide health care coverage to Americans, but found common ground on drug pricing and pharmaceutical importation.
Sanders and Cruz agreed that people should be able to purchase drugs from other countries, suggesting that it could create an environment of competition and lower U.S. prices. In January, both senators voted for an amendment to a budget resolution that would have allowed drug re-importation, but it did not pass. Read more
1. FDA to publicly share advisory committee CVs
The FDA’s ongoing commitment to transparency reached a new level last week, when the agency announced it would disclose the CVs of advisory committee members. The form will not include confidential or redacted information, said FDA.
Outside experts often weigh in on scientific and medical issues that pertain to new drugs and devices, and FDA has about 50 committees. These advisors are not subject to the conflict of interest rules adhered to by government employees. In June, however, an FDA draft guidance noted that both regular and special employees “must take appropriate steps to avoid even an appearance of violating these ethical principles.” Read more
The post MassDevice.com +5 | The top 5 medtech stories for February 8, 2017 appeared first on MassDevice.
from MassDevice http://ift.tt/2knn5vr
Cap comentari:
Publica un comentari a l'entrada